Elanco Animal Health Incorporated
ELANHealthcareNASDAQDrug Manufacturers - Specialty & Generic
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Elanco Animal Health Incorporated focuses on Drug Manufacturers - Specialty & Generic services and products. Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals worldwide. Valued at $11.91B, ELAN is a large-cap name in its sector. The company offers pet health products, such as parasiticides, vaccines, and therapeutics that protect pets from fleas, ticks, and internal parasites under the Seresto, K-9 Advantage, Advantix, and Advocate trademarks; prescription parasiticide products, an over-the-counter treatments for the prevention and elimination of fleas and ticks under the Credelio Family, Interceptor Plus, Drontal family, and Drontal Plus; vaccines portfolio that provides differentiated prevention coverage for a number of important pet health risks; and therapeutics portfolio for the treatment of pain, otitis, cardiovascular, and dermatology indications, as well as osteoarthritis for dogs and cats under the Galliprant trademark.
Market Cap
$11.91B
Beta
1.69
P/E (TTM)
—
P/E (Fwd)
19.65
EPS (TTM)
$-0.50
EPS (Fwd)
$1.21
ROE
-3.8%
ROA
1.5%
Cash
$428.0M
Total Debt
$4.30B
Free CF
$692.1M
52W Change
77.7%
Annual Financials
Cash vs Debt
The company holds $428.0M in cash, though total debt stands at $4.30B. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. The company generates $692.1M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. Return on equity stands at -3.8%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. ROA of 1.5% is on the lower side, which is common in asset-heavy industries. Revenue has been relatively flat, moving from $4.41B (2022) to $4.71B (2025).
With a beta above 1.5, ELAN tends to amplify broader market moves — both up and down. This higher volatility means larger price swings are common. The debt-to-cash ratio suggests meaningful leverage on the balance sheet, a factor worth monitoring if credit conditions tighten. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Elanco Animal Health Incorporated and its sector.